Results 171 to 180 of about 1,667,008 (303)

Alternative pathways to low carbon mobility

, 2013
Low carbon mobility is defined as mobility that results in substantially lower levels of carbon consumption and emissions. Here, mobility is defined as the total amount of travel that is undertaken on all forms of transport (Chapter 1), and carbon is used to illustrate the various negative environmental impacts from transport (Chapter 11). As discussed
openaire   +1 more source

Structural studies offer a framework for understanding the role of properdin in the alternative pathway and beyond. [PDF]

Immunol Rev, 2023
Pedersen DV, Lorentzen J, Andersen GR.
europepmc   +1 more source

Genetic attenuation of ALDH1A1 increases metastatic potential and aggressiveness in colorectal cancer

Molecular Oncology, EarlyView.
Aldehyde dehydrogenase 1A1 (ALDH1A1) is a cancer stem cell marker in several malignancies. We established a novel epithelial cell line from rectal adenocarcinoma with unique overexpression of this enzyme. Genetic attenuation of ALDH1A1 led to increased invasive capacity and metastatic potential, the inhibition of proliferation activity, and ultimately ...
Martina Poturnajova, Zuzana Kozovska, Ondrej Pos, Kristina Pavlov, Sachin Gulati, Peter Makovicky, Kristina Jakic, Monika Burikova, Eva Sedlackova, Barbora Svitkova, Silvia Tyciakova, Vojtech Bystry, Nicolas Blavet, Boris Tichy, Matej Hrnciar, Jaroslav Budis, Miroslav Tomas, Peter Dubovan, Georgina Kolnikova, Veronika Repaska, Nikoleta Mojzesova, Eva Zomborska, Daniel Pindak, Michal Mego, Tomas Szemes, Miroslava Matuskova   +25 more
wiley   +1 more source

Complement-Mediated Kidney Diseases: Role of Alternative Pathway in Glomerular Inflammation. [PDF]

Kidney Int Rep
Barratt J, Garred P, Lafayette RA, Zhang H, Floege J.   +4 more
europepmc   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Expression of Properdin, the positive regulator of the Complement Alternative Pathway, at the fetal-maternal interface in Preeclampsia. [PDF]

Front Immunol
Yasmin H, Roy T, Agostinis C, Rao A, Sharma P, Toffoli M, Balduit A, Pegoraro S, Bindu S, Prasad R, Ricci G, Vatish M, Madan T, Bulla R, Kishore U.   +14 more
europepmc   +1 more source

Bacterial outer membrane vesicles provide an alternative pathway for trafficking of <i>Escherichia coli</i> O157 type III secreted effectors to epithelial cells. [PDF]

mSphere, 2023
Sirisaengtaksin N, O'Donoghue EJ, Jabbari S, Roe AJ, Krachler AM.   +4 more
europepmc   +1 more source

RIPK4 function interferes with melanoma cell adhesion and metastasis

Molecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski, Sławomir Lasota, Ewelina Madej, Anna A. Brożyna, Małgorzata Szczygieł, Agnieszka Harazin‐Lechowska, Jan Czerbniak, Janusz Rys, Jaroslaw Czyz, Agnieszka Wolnicka‐Glubisz   +9 more
wiley   +1 more source

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays. [PDF]

Kidney Int Rep
Santarsiero D, Gastoldi S, Guaschino V, Bresin E, Pagani I, Pasini A, Romano E, Benigni A, Remuzzi G, Noris M, Aiello S.   +10 more
europepmc   +1 more source

The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target. [PDF]

Immunol Rev, 2023
Risitano AM, Frieri C, Urciuoli E, Marano L.   +3 more
europepmc   +1 more source